Search

During angiogenesis, new blood vessels headed by a migrating endothelial tip cell sprout from pre-existing ones. This process is known to be regulated by two signaling pathways concurrently, vascular endothelial growth factor A (VEGFA) and Notch-Delta. Extracellular VEGFA activates the intracellular Notch-Delta pathway in nearby endothelial cells which results in endothelial (stalk, tip) differentiation. Retinal astrocytes appear to play a crucial role in polarizing new sprouts by secreting VEGFA. \emph{In vivo} retinal angiogenesis experiments in neonatal mouse generated quantitative data on daily cell counts and morphological data of vascular network expanding over fibronectin-rich matrix. Based on this set of data and other existing ones, we developed a cell-based, multiscale mathematical model using the cellular Potts model framework to investigate the sprout evolution by integrating the VEGFA and Notch-Delta signaling pathways. The model incorporates three levels of description: intracellular, intercellular, and extracellular. Starting with a single astrocyte embedded in a fibronectin-rich matrix, we use the model to assess different scenarios regarding VEGFA levels and its interaction with matrix proteins. Simulation results suggest that astrocyte-derived VEGFA gradients along with heterogeneous ECM reproduces sprouting morphology, and the extension speed is in agreement with experimental data in 7 days postnatal mouse retina. Results also reproduce empirical observations in sprouting angiogenesis, including anastomosis, dynamic tip cell competition, and sprout regression as a result of Notch blockade., Comment: 33 pages, 16 figures

The past 5 years have witnessed a significant expansion in our understanding of vascular endothelial growth factor (VEGF) signaling. In particular, the process of canonical activation of VEGF receptor tyrosine kinases by homodimeric VEGF molecules has now been broadened by the realization that heterodimeric ligands and receptors are also active participants in the signaling process. Although heterodimer receptors were described 2 decades ago, their impact, along with the effect of additional cell surface partners and novel autocrine VEGF signaling pathways, are only now starting to be clarified. Furthermore, ligand-independent signaling (noncanonical) has been identified through galectin and gremlin binding and upon rise of intracellular levels of reactive oxygen species. Activation of the VEGF receptors in the absence of ligand holds immediate implications for therapeutic approaches that exclusively target VEGF. The present review provides a concise summary of the recent developments in both canonical and noncanonical VEGF signaling and places these findings in perspective to their potential clinical and biological ramifications.